The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas
- PMID: 35582008
- PMCID: PMC9019190
- DOI: 10.20517/cdr.2020.61
The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas
Abstract
Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of 15 months despite standard care therapy consisting of maximal surgical debulking, followed by radiation therapy with concurrent and adjuvant temozolomide treatment. The natural history of GBM is characterized by inevitable recurrence with patients dying from increasingly resistant tumor regrowth after therapy. Several mechanisms including inter- and intratumoral heterogeneity, the evolution of therapy-resistant clonal subpopulations, reacquisition of stemness in glioblastoma stem cells, multiple drug efflux mechanisms, the tumor-promoting microenvironment, metabolic adaptations, and enhanced repair of drug-induced DNA damage have been implicated in therapy failure. Extracellular vesicles (EVs) have emerged as crucial mediators in the maintenance and establishment of GBM. Multiple seminal studies have uncovered the multi-dynamic role of EVs in the acquisition of drug resistance. Mechanisms include EV-mediated cargo transfer and EVs functioning as drug efflux channels and decoys for antibody-based therapies. In this review, we discuss the various mechanisms of therapy resistance in GBM, highlighting the emerging role of EV-orchestrated drug resistance. Understanding the landscape of GBM resistance is critical in devising novel therapeutic approaches to fight this deadly disease.
Keywords: Glioblastoma; extracellular vesicles; radiation; resistance; temozolomide.
© The Author(s) 2021.
Conflict of interest statement
All authors declared that there are no conflicts of interest.
Figures

Similar articles
-
Extracellular Vesicles in Glioblastoma Tumor Microenvironment.Front Immunol. 2020 Jan 21;10:3137. doi: 10.3389/fimmu.2019.03137. eCollection 2019. Front Immunol. 2020. PMID: 32038644 Free PMC article. Review.
-
Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.Cancer Chemother Pharmacol. 2022 Feb;89(2):217-229. doi: 10.1007/s00280-021-04392-1. Epub 2022 Jan 17. Cancer Chemother Pharmacol. 2022. PMID: 35039898
-
Current insights on extracellular vesicle-mediated glioblastoma progression: Implications in drug resistance and epithelial-mesenchymal transition.Biochim Biophys Acta Gen Subj. 2022 Mar;1866(3):130065. doi: 10.1016/j.bbagen.2021.130065. Epub 2021 Dec 10. Biochim Biophys Acta Gen Subj. 2022. PMID: 34902452 Review.
-
Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.Cancer Sci. 2023 Jun;114(6):2609-2621. doi: 10.1111/cas.15773. Epub 2023 Mar 10. Cancer Sci. 2023. PMID: 36853018 Free PMC article.
-
Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism.Cell Death Dis. 2022 Apr 13;13(4):344. doi: 10.1038/s41419-022-04699-8. Cell Death Dis. 2022. PMID: 35418162 Free PMC article.
Cited by
-
An Update of Fungal Endophyte Diversity and Strategies for Augmenting Therapeutic Potential of their Potent Metabolites: Recent Advancement.Appl Biochem Biotechnol. 2025 May;197(5):2799-2866. doi: 10.1007/s12010-024-05098-9. Epub 2025 Feb 5. Appl Biochem Biotechnol. 2025. PMID: 39907846 Free PMC article. Review.
-
Analysis of regulatory sequences in exosomal DNA of NANOGP8.PLoS One. 2023 Jan 25;18(1):e0280959. doi: 10.1371/journal.pone.0280959. eCollection 2023. PLoS One. 2023. PMID: 36696426 Free PMC article.
-
The Role of Intracellular and Extracellular Vesicles in the Development of Therapy Resistance in Cancer.Curr Pharm Des. 2024;30(35):2765-2784. doi: 10.2174/0113816128326325240723051625. Curr Pharm Des. 2024. PMID: 39113303 Review.
-
Computational Mutagenesis and Inhibition of Staphylococcus aureus AgrA LytTR Domain Using Phenazine Scaffolds: Insight From a Biophysical Study.Biomed Res Int. 2024 Sep 18;2024:8843954. doi: 10.1155/2024/8843954. eCollection 2024. Biomed Res Int. 2024. PMID: 39328594 Free PMC article.
-
Overcoming drug resistance in glioblastoma: new options in sight?Cancer Drug Resist. 2021 Jun 19;4(2):512-516. doi: 10.20517/cdr.2021.03. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582029 Free PMC article. No abstract available.
References
-
- Stupp R, Mason WP, van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Oncol Times. 2005;27:15–6. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources